Exploring Symprove product for the management of GORD symptoms
A pilot study exploring the use of Symprove for the management of gastroesophageal reflux symptoms
- Hospital – Speciality: Wythenshawe Hospital, Gastroenterology
- Study type: Other clinical trial study (a novel intervention)
- Funder: Symprove Ltd
Summary
The aim of our pilot study is to assess the impact of a gut supplement called Symprove on gastro-oesophageal symptoms. Symprove is a water-based solution that contains billions of live and active bacteria, which can help stimulate the good bacteria already in the gut. This will be a 6-week non-randomised study, which involves one study visit and six weekly follow-up calls. All participants will receive Symprove delivered to their home to take once a day. Participants will complete two questionnaires (RESQ-7, IBS-SSS) at the Baseline study visit. The same questionnaires will be completed over the phone at each follow-up call.
Participant group
Patients investigated for reflux symptoms
Participant approach
The clinical team will identify patients who may be eligible from clinic visits or clinic lists.
Study open date and expected length
Opened: June 2026
Results
Pending – this study is still active.
Contact details
Email address: sharon.archbold@mft.nhs.uk / sorela.maziluwood@mft.nhs.uk
Telephone number: 01612914188
- IRAS number: 364448
